Texas Heart Institute Discovery targets inflammatory disease for patients suffering from IBD (IMAGE)
Caption
Aviara Pharmaceuticals, Inc. to collaborate with the Texas Heart Institute (THI) to develop a small molecule drug that targets inflammatory cell trafficking to the gut as a safe alternative to current treatment strategies in inflammatory bowel disease (IBD).
Credit
Photo Credit: Texas Heart Institute
Usage Restrictions
None
License
Licensed content